Subcutaneous · Amylin analog
ABBV-295
4 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
4
Active
3
Recruiting
2
Completed
1
Sites
3
Countries
2
Endpoints
27
Composite endpoints
3
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
4
Trials by status
Recruiting
2
Active, not recruiting
1
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
23
Weight & body composition
2
Glycemic / diabetes
1
Other (unclassified)
1
Most-measured metrics
Top 20 metrics across this asset's endpoints
Treatment-emergent AEs (any)Safety/PK
1
TmaxSafety/PK
1
AUC₀–∞Safety/PK
1
Half-lifeSafety/PK
1
Body weight, absolute change (kg)Weight
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
4 of 4
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07291232A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity | ABBV-295 Obesity / overweight | BMI 30-45 | Ph 1 | Recruiting | 2 | Oct 2026 | — | |
| NCT07414784A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives | ABBV-295 | BMI 25-35 | Ph 1 | Active, not recruiting | 2 | Jul 2026 | — | |
| NCT07514260A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity. | ABBV-295 | BMI 23-35 | Ph 1 | Recruiting | 1 | Jan 2027 | — | |
| NCT06144684A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295 | ABBV-295 Healthy volunteers, Obesity / overweight | BMI 22-32 | Ph 1 | Completed | 1 | Jan 2026 | — |